The Drug Supply Chain Security Act, part of the Drug Quality and Security Act signed by President Obama in 2013, demands error-free serialization and tracking of pharmaceutical products throughout the entire supply chain. In November 2017, pharmaceutical manufacturers will be expected to comply with item-serialization requirements, with requirements for repackagers to follow in 2018.
With expertise in factory intelligence and secure item tracking, Bell and Howell will be hosting a complimentary Southeast Traceability & Serialization Forum on November 17 to help pharmaceutical companies learn from their peers and other experts about how to refine their path to compliance with the DSCSA. The event will be held at Bell and Howell’s facility at 3791 South Alston Avenue in Durham, North Carolina.
Attendees will be able to spend time with industry experts as they deliver a comprehensive review of the DSCSA; engage in discussion on the supply chain’s evolving demands and threats to existing serialization-line solutions; and expand their network of peers who can help work through the challenges of compliance.
“Rapid changes in the global regulatory environment, including the enactment of the Drug Supply Chain Security Act here in the USA, are driving the need for serialization in the pharmaceutical supply chain,” says Roger Saumure, President of Excellis Health Solutions. “Events like the Southeast Traceability & Serialization Forum can help educate and empower compliance and logistics professionals whose companies are affected by these regulations.”
The event will include Kevan MacKenzie, Director of Serialization Technology at McKesson; Randy Feldman, Chief Solution Architect at Excellis Health Solutions; and Andy Meyer, Serialization Lead and Senior Systems Analyst at North Carolina Mutual Wholesale Drug Company.
The agenda for the Southeast Traceability & Serialization Forum includes the following activities:
• Industry Track and Trace Updatem Excellis Health Solutions. Understanding and meeting evolving regulations for the entire supply chain.
• Final Findings from Recent HDA Supply Chain Trial. Two study participants sharing the outcomes of the Healthcare Distributor Alliance’s pilot study for saleable returns.
• Interactive Serialization Concerns Discussion. With an eye toward future serialization deadlines, what worries drug companies most? What’s next? Who can help?
• Panel Discussion of Lessons Learned. Industry leaders and peers discussing unexpected issues, real-world solutions, business unit involvement, risk management, and true timelines.
• Live Hardware and Data Management Software Solution Demonstrations.
“We are thrilled to be able to bring the regional pharmaceutical community together to discuss this important topic,” says Larry Blue, Bell and Howell’s Chief Operating Officer. “The impact the DSCSA is having on the industry’s supply chain cannot be overstated. But we have put together an information-packed day with industry experts and some amazing demonstrations to help guide us.”
Bell and Howell delivers service and technology solutions that enrich customer communications and fulfillment for the world’s largest finance, industry and public sector enterprises. The company helps its customers streamline high-volume, high-integrity production of customer communications and product fulfillment, track delivery throughout the supply chain, maximize postal discounts, and monetize customer touchpoints.